TherapeuticsMD (TXMD)
Collects royalties from women’s-health products licensed to pharmaceutical partners.
$2.30
At close+0.13 (+5.99%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Cost of revenue | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| 2 | 1 | 1 | 3 | 2 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | |
| 2 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | |
| Selling & marketing | 0 | −2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 3 | 0 | 0 | 2 | 0 | 1 | 0 | 2 | 2 | 1 | 2 |
| Other expenses | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −2 | −2 | −1 | −3 | −1 | 0 | −1 | −1 | −1 | −1 | −1 | −1 |
| 0 | 0 | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | −2 | −1 | 1 | 0 | −1 | −1 | 3 | 0 | 0 |
| Income before tax | −1 | −2 | −1 | −1 | −1 | 0 | −1 | 1 | 0 | −1 | 0 | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −1 | −2 | −1 | −1 | −1 | 0 | −1 | 1 | 0 | −1 | 0 | 0 |
| Discontinued operations | −2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −3 | −1 | −1 | −1 | −1 | 0 | −1 | 1 | 0 | −1 | 0 | 0 |
| EPS, basic | −$0.32 | −$0.08 | −$0.06 | −$0.09 | −$0.05 | $0.02 | −$0.06 | $0.05 | $0.01 | −$0.05 | $0.01 | $0.01 |
| EPS, diluted | −$0.32 | −$0.08 | −$0.06 | −$0.09 | −$0.05 | $0.02 | −$0.06 | $0.05 | $0.01 | −$0.05 | $0.01 | $0.01 |
| Weighted average shares, basic | 11 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Weighted average shares, diluted | 11 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| EBITDA | −1 | −1 | −1 | −1 | 0 | −1 | −1 | 1 | 0 | −3 | −1 | 0 |
| Depreciation & amortization | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| EBIT | −1 | −1 | −1 | −1 | −1 | −1 | −1 | 1 | 0 | −4 | −1 | −1 |